JPRN-jRCT2080221938未知3 期
A 14 week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 in comparison to olmesartan in elderly patients with essential hypertension
ovartis Pharma K.K.0 个研究点目标入组 576 人开始时间: 2012年10月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 576
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 65age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients must give written informed consent before any assessment is performed
- •- Patients with essential hypertension, untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure(msSBP) >= 150 mmHg and < 180 mmHg
- •- Patients must be able to communicate and comply with all study requirements and demonstrate good medication compliance
排除标准
- •- Patients with severe hypertension. Patients with history of angioedema, drug-related or otherwise
- •- Patients with history or evidence of a secondary form of hypertension
- •- Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke
- •- History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1
- •- Current angina pectoris requiring medication (other than patients on a stable dose of oral or topical nitrates)
- •- Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled and are not on a stable dose of antidiabetic medication
- •- Patients with previous or current diagnosis of heart failure (NYHA Class II-IV)
- •- Patients with a clinically significant valvular heart disease at the time of screening
- •- Women of child-bearing potential, who do not use adequate birth control methods
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2022-002757-26-BGHMNC Holding GmbH324
进行中（未招募）
1 期
.MedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2022-002757-26-LTHMNC Holding GmbH324
已完成
2 期
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)Major Depressive Disorder2024-513104-34-00HMNC Holding GmbH274
进行中（未招募）
不适用
A 13-week, multicenter, randomized, double-blind, double-dummy,placebo-controlled, parallel group trial oflumiracoxib (COX189) 100 mg o.d. in patients with primaryhip osteoarthritis using celecoxib (200 mg o.d.) as apositive controlMedDRA version: 8.0Level: LLTClassification code 10020108Primary osteoarthritis of the hipEUCTR2005-002772-14-DEovartis Pharma Services AG1,200
进行中（未招募）
不适用
A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib 200 mg o.d. as a positive controlMedDRA version: 6.1Level: PTClassification code 10024776OsteoarthritisEUCTR2005-002772-14-ITOVARTIS FARMA1,200